Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Beghetti, M. Gatzoulis, J. Granton, R. Berger, Andrea Lauer, E. Chiossi, M. Landzberg (2006)
Double-Blind , Randomized , Placebo-Controlled Study Bosentan Therapy in Patients With Eisenmenger Syndrome : A Multicenter
Simo Taimela, A. Malmivaara, Selina Justén, Esa Läärä, Harri Sintonen, Jaakko Tiekso, Timo Aro (2007)
The effectiveness of two occupational health intervention programmes in reducing sickness absence among employees at risk. Two randomised controlled trialsOccupational and Environmental Medicine, 65
S. Apostolopoulou, A. Manginas, D. Cokkinos, S. Rammos (2006)
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year studyHeart, 93
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationThe BMJ, 339
N. Galiè, Lewis Rubin, M. Hoeper, P. Jansa, H. Al-hiti, G. Meyer, E. Chiossi, Andjela Kusic-Pajic, G. Simonneau (2008)
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trialThe Lancet, 371
N. Galiè, A. Manes, M. Palazzini, L. Negro, A. Marinelli, S. Gambetti, E. Mariucci, A. Donti, A. Branzi, F. Picchio (2012)
Management of Pulmonary Arterial Hypertension Associated with Congenital Systemic-to-Pulmonary Shunts and Eisenmenger’s SyndromeDrugs, 68
V. Thakkar, E. Lau (2016)
Connective tissue disease-related pulmonary arterial hypertension.Best practice & research. Clinical rheumatology, 30 1
Joe Anderson, J. Nawarskas (2010)
Pharmacotherapeutic management of pulmonary arterial hypertension.Cardiology in review, 18 3
S. Antoniu (2005)
Bosentan for treatment of pulmonary arterial hypertension (I)Therapy, 2
Mi-Ma Duo-Ji, Z. Long (2017)
Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.International journal of cardiology, 234
O. Sitbon, Maurice Beghetti, Jérôme Petit, L. Iserin, Marc Humbert, V. Gressin, G. Simonneau (2006)
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defectsEuropean Journal of Clinical Investigation, 36
N. Galiè, Marc Humbert, J. Vachiéry, S. Gibbs, Irene Lang, Adam Torbicki, G. Simonneau, Andrew Peacock, A. Noordegraaf, Maurice Beghetti, A. Ghofrani, Miguel Sánchez, Georg Hansmann, W. Klepetko, Patrizio Lancellotti, Marco Matucci, Theresa McDonagh, Luc Piérard, Pedro Trindade, Maurizio Zompatori, M. Hoeper (2016)
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.Revista espanola de cardiologia, 69 2
S. Raja (2010)
Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.Cardiovascular therapeutics, 28 5
V. Mclaughlin (2006)
Survival in patients with pulmonary arterial hypertension treated with first‐line bosentanEuropean Journal of Clinical Investigation, 36
E. Gabbay, J. Fraser, K. McNeil (2007)
Review of bosentan in the management of pulmonary arterial hypertensionVascular Health and Risk Management, 3
M. Humbert, R. Barst, I. Robbins, R. Channick, N. Galiè, A. Boonstra, L. Rubin, E. Horn, A. Manes, G. Simonneau (2004)
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2European Respiratory Journal, 24
G. Castro (2001)
[Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 20 11
V. McLaughlin, Melinda Davis, W. Cornwell (2011)
Pulmonary arterial hypertension.Current problems in cardiology, 36 12
(2006)
Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &
Xinwang Chen, Z. Zhai, K. Huang, W. Xie, J. Wan, Chen Wang (2018)
Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta‐analysisThe Clinical Respiratory Journal, 12
R. Baptista, G. Castro, A. Silva, P. Monteiro, L. Providência (2013)
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 32 2
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLoS Medicine, 6
I. Schulze-Neick, N. Gilbert, R. Ewert, C. Witt, E. Gruenig, B. Enke, M. Borst, P. Lange, M. Hoeper (2005)
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy.American heart journal, 150 4
R. Channick, G. Simonneau, O. Sitbon, I. Robbins, A. Frost, V. Tapson, D. Badesch, S. Roux, M. Rainisio, F. Bodin, L. Rubin (2001)
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 358
G. Diller, K. Dimopoulos, M. Kaya, C. Harries, A. Uebing, Wei Li, Evdokia Koltsida, J. Gibbs, M. Gatzoulis (2007)
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart diseaseHeart, 93
R. You, Xinyu Qian, Weijing Tang, Tian Xie, F. Zeng, Jun Chen, Yu Zhang, Jinyu Liu (2018)
Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic ReviewCanadian Respiratory Journal, 2018
Xiantao Zeng, Yonggang Zhang, J. Kwong, Chao Zhang, Sheng Li, F. Sun, Y. Niu, L. Du (2015)
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic reviewJournal of Evidence‐Based Medicine, 8
M. D'alto, E. Romeo, P. Argiento, A. D’Andrea, B. Sarubbi, A. Correra, G. Scognamiglio, S. Papa, E. Bossone, R. Calabrò, C. Vizza, M. Russo (2013)
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.International journal of cardiology, 164 3
Rolf Berger, Sheila Haworth, D. Bonnet, Y. Dulac, A. Fraisse, N. Galiè, D. Ivy, X. Jaïs, O. Miera, E. Rosenzweig, M. Efficace, Andjela Kusic-Pajic, M. Beghetti (2016)
FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.International journal of cardiology, 202
A. Peacock, N. Murphy, J. McMurray, L. Caballero, S. Stewart (2007)
An epidemiological study of pulmonary arterial hypertensionEuropean Respiratory Journal, 30
H. Hsu, Jin-Shing Chen, R. Chen, W. Ko, Shuenn-Wen Kuo, E. Wu, Mei-Hwan Wu, Jou-Kou Wang, Yung‐Chie Lee (2007)
Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.Respiratory medicine, 101 7
L. Rubin, D. Badesch, R. Barst, N. Galiè, C. Black, A. Keogh, T. Pulido, A. Frost, S. Roux, I. Leconte, M. Landzberg, G. Simonneau (2002)
Bosentan therapy for pulmonary arterial hypertension.The New England journal of medicine, 346 12
K. Lewis (2008)
Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled StudyGaliè N, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators (Università di Bologna, Italy; Hpital des Enfants, Geneva; Imperial CollegeYearbook of Pulmonary Disease
R. Benza, Dave Miller, R. Barst, D. Badesch, A. Frost, M. McGoon (2012)
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.Chest, 142 2
J. Vis, M. Duffels, P. Mulder, R. Bruin-Bon, B. Bouma, R. Berger, E. Hoendermis, A. Dijk, B. Mulder (2013)
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.International journal of cardiology, 164 1
V. Mclaughlin, O. Sitbon, D. Badesch, Rj Barst, C. Black, N. Galiè, M. Rainisio, G. Simonneau, Lewis Rubin (2005)
Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 25
P. Hassoun (2009)
Pulmonary arterial hypertension complicating connective tissue diseases.Seminars in respiratory and critical care medicine, 30 4
B. Degano, A. Yaici, J. Pavec, L. Savale, X. Jaïs, B. Camara, M. Humbert, G. Simonneau, O. Sitbon (2009)
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertensionEuropean Respiratory Journal, 33
R. Girgis, S. Mathai, J. Krishnan, F. Wigley, P. Hassoun (2005)
Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 24 10
M. Kaya, Y. Lam, B. Erer, S. Ayhan, M. Vatankulu, Z. Nurkalem, M. Meriç, M. Eren, N. Eryol (2012)
Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome.Journal of cardiac failure, 18 5
Avid, B. B., Adesch, Daani, Rost, Ébastien, oux, Sabelle, E.Conte, Érald, Imonneau, F. thE, Osentan, Andomized, O. Rial, Ndothelin (2002)
BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION
S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jaïs, G. Simonneau (2006)
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.European heart journal, 27 5
F. Cozzi, R. Montisci, H. Marotta, F. Bobbo, N. Durigon, M. Ruscazio, P. Sfriso, S. Iliceto, S. Todesco (2006)
Bosentan therapy of pulmonary arterial hypertension in connective tissue diseasesEuropean Journal of Clinical Investigation, 36
ObjectiveThis systematic review and meta-analysis was conducted to identify if long-term bosentan is an effective and safe treatment for pulmonary arterial hypertension (PAH) regardless of type, including idiopathic PAH (IPAH), and PAH associated with congenital heart disease (APAH-CHD), connective tissue disease (APAH-CTD), and human immunodeficiency virus (APAH-HIV).MethodsAll relevant observations were systematically searched by two independent investigators and obtained from three databases, including PubMed, EMBASE and the Cochrane Library, from the inception of each database to February 2020. Currently, long-term administration was defined as no less than 12 months. A random-effects or fixed-effects model was selected according to outcomes of the heterogeneity test for meta-analysis, where standardized mean difference (SMD) with 95% confidence intervals (CIs) was used for continuous outcomes, in addition to the estimated effect (ES; 95% CI) for the synthesized survival rate. Furthermore, subgroup analysis was applied to analyze the differences of efficacy and survivals in each type of PAH cohort.ResultsFifteen studies including a total of 659 subjects undergoing oral bosentan administration for at least 12 months were pooled in this quantitative review. Meta-analysis and subgroup analysis indicated that significant clinical benefits existed, including an improved 6-min walk distance (6MWD) and functional class (FC), in patients with APAH-CHD (6MWD: SMD 0.72, 95% CI 0.52–0.93, p < 0.0001; functional benefits: 50.4%, 95% CI 43.7–57.1%), APAH-HIV (6MWD: SMD 0.83, 95% CI 0.36–1.30, p = 0.001; functional benefits: 80.4%), and IPAH (SMD 0.54, 95% CI 0.28–0.80, p < 0.0001; functional benefits: 61.4%, 95% CI 54.2–68.5%), but a non-significant change in APAH-CTD (6MWD: SMD 0.18, 95% CI − 0.60 to 0.95, p = 0.656; functional benefits: 27.5%). Furthermore, among the hemodynamic parameters, long-term bosentan led to a significant decrease in mean pulmonary artery pressure (SMD − 0.86, p < 0.0001) in APAH-CTD, and a decrease in pulmonary vascular resistance (SMD − 0.65, p < 0.0001) and elevated oxygen saturation (SMD 0.30, p = 0.006) in APAH-CHD. Importantly, in all pooled studies, the overall survival indicated 1-, 2-, and 3-year survival rates of 94.3%, 88.8%, and 81.7%, respectively, in all-cause PAH, and subgroup analysis demonstrated a relative decreasing trend in patients with HIV, from a 2-year survival of 89.8% to a 3-year survival of 66.1%. Adverse drug reactions were relatively mild.ConclusionIn this systematic review and meta-analysis, long-term administration of oral bosentan has been identified as a well-tolerated and effective agent in different types of PAH. In addition, we conclude that long-term oral bosentan should be considered for patients with CTD to achieve a satisfactory exercise capacity, and for those with APAH-HIV to improve survivals, where more attention on adverse events is required.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 12, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.